Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
August 2011, Vol 2, No 5
August 2011, Vol 2, No 5
Screening for Pancreatic Cancer Is Effective, Has Value— at Least in High-Risk Individuals
By
Caroline Helwick
Cancer Care
,
Personalized Medicine
August 2011, Vol 2, No 5
Ongoing efforts to screen asymptomatic persons for pancreatic cancer have been unsuccessful, but targeting persons at high risk for the disease appears to be clinically effective as well as cost-effective.
Read Article
Post-ASCO Survey: Oncologists’ and Payers’ Treatment and Coverage Decisions
By
Caroline Helwick
Economics & Value
,
Reimbursement
August 2011, Vol 2, No 5
An analysis of payer and provider responses to key clinical information presented at the ASCO 2011 annual meeting offers a glimpse of the oncology landscape shared by oncologists and health plans.
Read Article
Impact of EHRs on Oncology Practice: Enhancing the Value of Cancer Care
By
Gena Cook
Practice Management
,
Value Peer-spectives
August 2011, Vol 2, No 5
Widespread adoption of information technology (IT) is now regarded as a pathway to improving healthcare and achieving the highly regarded goals for redesigning care.
Read Article
Dose-Monitoring, Split-Fill Programs Reduce Oral Chemotherapy Waste, Save Costs
By
Caroline Helwick
Oncology
August 2011, Vol 2, No 5
Dose-monitoring programs for oral chemotherapy drugs can reduce wastage and reduce the risk of serious adverse effects associated with these drugs.
Read Article
Accountable Care Organizations: Implications for Cancer-Related Quality Care and Spending
By
Caroline Helwick
Health Policy
,
Policies & Guidelines
August 2011, Vol 2, No 5
ACOs are believed to hold the potential for addressing variation in quality and costs of cancer care, but their impact will depend on buy-in and leadership among oncologists, according to David Miller, MD, MPH, a urologic surgeon and health services researcher at the University of Michigan, Ann Arbor. He addressed this topic during the recent annual meeting of the American Society of Clinical Oncologists.
Read Article
Hanging in Limbo: What Does Deficit Reduction Mean for Oncology?
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
August 2011, Vol 2, No 5
On August 2, 2011, President Obama signed the Budget Control Act of 2011 into law, the result of a month-long partisan battle over raising the federal debt ceiling and, in the long-term, reducing the federal deficit (Budget ControlAct of 2011. Pub. L. No. 112-25).
Read Article
Comparing the Value of Denosumab versus Zoledronic Acid in Preventing Cancer-Related Skeletal Events
By
Caroline Helwick
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Two agents are vying to be the preferred option for bone protection in patients with cancer—the blockbuster drug zoledronic acid (ZA; Zometa, Reclast) and the newer drug denosumab (Prolia), which was approved last year for the prevention of skeletal-related events (SREs) in patients with cancer.
Read Article
Prolonged Treatment with Imatinib for High-Risk GIST Increases Survival, Reduces Recurrence
By
Audrey Andrews
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Results from a phase 3 clinical trial presented at a plenary session at ASCO 2011 could lead to prolonged treatment with adjuvant imatinib for gastrointestinal stromal tumors (GIST).
Read Article
The Oncology Drug Pipeline Is Promising
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Studies presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) suggest that patients with metastatic mel anoma or with non– small-cell lung cancer (NSCLC)—2 disease states with very high rates of mortality—may soon have new treatment options.
Read Article
Off-Label Drug Use, Advanced Technologies Driving Up Medicare Cost of Cancer Care
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—A series of studies presented at this year’s ASCO annual meeting suggest that the use of unwarranted high-cost imaging procedures, a surge in the use of innovative treatment technologies, and off-label use of supportive cancer agents are helping to escalate Medicare costs, leading researchers to suggest that further regulation may be needed to rein in unnecessary expenses.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma